Browsing by Author "Bankole, Adegbenga"

Now showing 1 - 7 of 7
  • Thumbnail Image
    A Case of Hyperviscosity Syndrome in Rheumatoid Arthritis
    Shah, Viraj; Husain, Hyder; Bankole, Adegbenga; Kazmi, Taskeen; Greear, Emma; Henderson, Carl (American College of Physicians, 2023-05-01)
    Hyperviscosity syndrome (HVS) is a rare complication of bothmonoclonal and polyclonal disorders associated with elevation of immunoglobulins. Here, we describe a female patient who presented with shortness of breath and a history of seropositive rheumatoid arthritis with deformities, significant barriers to care, and poor therapeutic adherence. Her rheumatoid factor titer was greater than 1000 kIU/L, and she had an elevated serum viscosity level with her presentation consistent with HVS which improved significantly after therapeutic plasmapheresis. Our case highlights the presentation of rare but potentially life-threatening HVS that can occur in patients with systemic autoimmune rheumatic disorder.
  • Thumbnail Image
    A Case of Immune Mediated Necrotizing Myositis
    Shah, Viraj; Young, Lena; Husain, Hyder; Kazmi, Taskeen; Bankole, Adegbenga (Elsevier, 2023-04-22)
  • Thumbnail Image
    Establishing A Multidisciplinary Clinic To Improve The Quality Of Care For Patients With Interstitial Lung Disease
    Bankole, Adegbenga; Kazmi, Taskeen; Strazanac, Alyssa; Scheuing, William; Fleming, Jessica (2022-06-03)
  • Thumbnail Image
    Glucocorticoid induced osteoporosis: Increased awareness as a management strategy for prevention of this complication in patients with systemic autoimmune rheumatic disease
    Bankole, Adegbenga; Greear, Emma L. (AVES Yayincilik, 2023-08)
    Background: It has been estimated that about 1% of the US population is treated with long-term glucocorticoids. High doses of glucocorticoids particularly those used by rheumatologists and others for systemic autoimmune rheumatic disease result in bone loss, causing glucocorticoid-induced osteoporosis and an increase in the risk of fractures. The increased risk is related to both the daily dose and the cumulative dose of the glucocorticoids. Despite the availability of effective preventative and treatment options, glucocorticoid-induced osteoporosis is often not mitigated with the use of these preventive therapies. The risk of glucocorticoid-induced osteoporosis often also goes underrecognized, because it occurs in a different group of patients compared to age-related osteoporosis. As a result, glucocorticoid-induced osteoporosis is not always treated until after fractures may have occurred. Our objective is to determine if a structured health-care provider’s educational intervention with intermittent educational updates would lead to improvement in the identification, evaluation, and prevention of glucocorticoid-induced osteoporosisin those patients at the highest risk of glucocorticoid-induced osteoporosis. Methods: In this single-center, prospective study, patients over 40 years of age, receiving a total cumulative dose of glucocorticoids of >5 g or a single dose of >30 mg of prednisone or its equivalent was enrolled. All providers attended an academic Journal Club, where the current American College of Rheumatology guidelines regarding glucocorticoid-induced osteoporosiswas reviewed. All providers received monthly reminders during academic meetings within the department. Results: There was a statistically significant improvement between pre- and post-educational data, with increasing use of glucocorticoid-induced osteoporosis preventive measures, which was sustained over the 12-month duration of the study. Conclusion: This research shows the importance of provider education as a means of disseminating information and improving the quality of patient care.
  • Thumbnail Image
    An Interesting Image of Gout Crystals with Surrounding Tophi
    Husain, Hyder; Shah, Viraj; Bankole, Adegbenga (Elsevier, 2023-08)
  • Thumbnail Image
    A review of neonatal lupus syndrome
    Bankole, Adegbenga; Nwaonu, Jane (Sage, 2024-09-17)
    This review article discusses neonatal lupus syndrome (NLS), an immune-mediated disease caused by maternal antibodies. Maternal antibodies in the fetal circulation are mostly but not always protective. NLS is a disease caused by pathogenic maternal autoantibodies in the fetal circulation. The passive immunization of the fetus by NLS-causing maternal antibodies may occur in the absence of a previously known maternal systemic autoimmune rheumatic disease (SARD). Screening for NLSrelated antibodies in patients with related SARD or those in whom there is a risk of NLS including first-degree relatives should occur before pregnancy. This screening is best performed as part of a collaborative relationship between obstetrics and rheumatology. Pregnancy preparations in those with SARD include transitioning to pregnancy-safe medications. The symptoms of NLS range from minor skin rashes to fetal demise from heart block. Fetal screening allows for maternal therapeutic interventions that may be beneficial, as well as the use of fetal pacemakers in the more severe cases that include cardiac NLS.
  • Thumbnail Image
    Voclosporin
    Shah, Viraj R.; Bankole, Adegbenga (2023-06-01)